Genmab A (GMAB) Acquisitions (2024)

Genmab A's (GMAB) quarterly Acquisitions came in at -$1.8 billion in Q4 2024, little changed on a QoQ basis from -$1.8 billion in Q3 2024.

Genmab A (GMAB) Acquisitions (2024) Analysis & Trends

Genmab A (GMAB) has 1 years of Acquisitions data on file, last reported at -$1.8 billion in Q4 2024.

Quarterly Acquisitions changed N/A year-over-year to -$1.8 billion in Q4 2024, while the trailing twelve-month figure through Jun 2025 was -$5.3 billion (changed N/A YoY) and the FY2025 annual result came in at -$7.2 billion, changed N/A from the prior year.
Acquisitions was little changed at -$1.8 billion in Q4 2024, from -$1.8 billion in the prior quarter.
In the past five years, Acquisitions ranged from a high of -$1.8 billion in Q2 2024 to a low of -$1.8 billion in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Genmab A	2.05 Bn	548.77 Mn	1.07 Bn	-

Download Data